Ilmarinen Mutual Pension Insurance Co grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 3.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 57,200 shares of the medical research company’s stock after purchasing an additional 1,900 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Thermo Fisher Scientific were worth $38,613,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. BlackRock Inc. bought a new stake in Thermo Fisher Scientific during the second quarter worth approximately $15,501,867,000. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $382,547,000. Bank of New York Mellon Corp acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $1,974,561,000. Bank of America Corp DE bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after acquiring an additional 22,827 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.
Thermo Fisher Scientific News Summary
Here’s some of the latest news about TMO:
- Positive Sentiment: Thermo Fisher introduced Gibco VaxEvo CD 293 Medium, an animal-origin-free medium designed to support adenovirus production for vaccine developers. The product could help simplify bioproduction workflows, though its financial contribution is not yet clear. Article: How Investors May Respond To Thermo Fisher Scientific (TMO) Adenovirus Medium Launch
- Positive Sentiment: A market report forecasts the global refrigerated-incubator market will grow from $637 million in 2025 to $846.9 million by 2032. Thermo Fisher is among the companies serving this market, which could offer a modest demand tailwind. Article: Refrigerated Incubators – Global Strategic Business Report 2026
- Neutral Sentiment: One recent review says TMO has gained 1.8% since its earnings report and examines estimates for clues about what may come next, but the available summary provides no specific forecast changes. Article: Thermo Fisher Up 1.8% Since Last Earnings Report
Insiders Place Their Bets
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of the company’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the transaction, the vice president directly owned 11,560 shares in the company, valued at approximately $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.33% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the company. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an “outperform” rating for the company. Deutsche Bank increased their price target on Thermo Fisher Scientific from $720.00 to $750.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $690.00 to $760.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Finally, Evercore cut their price objective on Thermo Fisher Scientific from $720.00 to $615.00 and set an “outperform” rating on the stock in a report on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $683.64.
Get Our Latest Report on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
Shares of TMO opened at $668.89 on Friday. The company’s 50 day moving average price is $678.63 and its 200 day moving average price is $559.30. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $727.56. The company has a market capitalization of $247.84 billion, a PE ratio of 35.28, a PEG ratio of 2.82 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the prior year, the business earned $5.79 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 9.92%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
